source
- Merck projects continued investment and growth as Keytruda patent expiresMerck reported third‑quarter results on an investor call, saying sales expectations were above forecasts thanks to strong performance of subcutaneous Keytruda and the pulmonary arterial hypertensio…
- Merck says 2027 will focus on pipeline and new product launches despite recent trial winsMerck's chief financial officer said the company views 2027 as another year of investment, emphasizing its expanding pipeline and upcoming product launches rather than short‑term margin growth. Th…